Repertoire Immune Medicines and BMS Partner to Develop Tolerizing Vaccines for Autoimmune Diseases
Shots:
- Repertoire & BMS have signed a multi-year strategic agreement to develop tolerizing vaccines addressing up to 3 autoimmune disorders. Repertoire will handle activities up to development candidate nomination & BMS will be responsible for clinical evaluations, regulatory activities & commercialization
- Repertoire will discover & develop candidates through its DECODE platform (TCR-epitope discovery platform) & lipid nanoparticle delivery technology. It will further monitor their immune responses to offer insights into vaccine pharmacodynamics
- Under the collaboration, Repertoire is entitled to receive $65M upfront, ~$1.8B development, regulatory & commercial milestones along with tiered royalties
Ref: Repertoire | Image: Repertoire
Related News:- Repertoire Collaborates with Yale University to Identify Novel Antigen and T- Cell Receptor for Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
